Newborn Screening for Cystic Fibrosis Is Associated With the Lowest Healthcare Costs: A 10‐Year Observational Follow‐Up Study in France
Pediatric Pulmonology · 2025
DOI: 10.1002/ppul.71134 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Erika Guyot und 9 weiteren Autor:innen. Beteiligte Einrichtung: PELyon, PharmacoEpidémiologie Lyon, Lyon, France. Hauptthemen laut MEDLINE: Cystic Fibrosis, Health Care Costs, Neonatal Screening. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This study was supported by the French patient organization "Vaincre La Mucoviscidose", which participated in providing data from the French Registry, in the i….
Abstract (Originalsprache)
Objectives
This study aims to study the healthcare (HC) costs associated with cystic fibrosis (CF) in children diagnosed prenatally (ANT), through newborn screening (NBS), after birth due to meconium ileus (MI), or later based on symptoms (LS). Additionally, it seeks to clinically characterize children with CF (chCF) with different trajectories of HC costs. Study Design A retrospective observational study was conducted on data from the French CF Registry (FCFR) and the French National Claims Database (SNDS) linked from 2006 to 2021. HC costs related to CF diagnosis circumstances were estimated per year of life among chCF up to age 10. Group‐based trajectory modeling was performed to identify subgroups with similar cost trajectories.
Results
Between 2006 and 2011, data from 1065 chCF were recorded in the FCFR. Nine hundred seventy‐three (91.4%) were matched with SNDS, and 779 (73.1%) had at least 10 years of follow‐up. During the first year, HC costs of chCF diagnosed with NBS were lower than for those diagnosed with MI and ANT (all p < 0.05). However, by the tenth year HC were no longer different between groups. Three groups with different cost trajectories were identified. Groups with the highest costs had a lower lung function at 6 and 10 years and the lowest weight and height z ‐scores at 2 and 10 years (all p < 0.05).
Conclusion
NBS is associated with the lowest HC costs during the first year of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- PELyon, PharmacoEpidémiologie Lyon, Lyon, France.
- RESearch on HealthcAre PErformance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France.
- Service de Pneumologie, Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Lyon, France.
- Centre de Reference de la Mucoviscidose et Maladies Apparentées, Hôpital Necker Enfants Malades, Paris, France.
- INSERM U 1151, Institut Necker Enfants Malades, Université Paris Cité, ERN Lung, Paris, France.
- Service de pédiatrie, Centre Hospitalier Universitaire, Saint Etienne, France.
ORCID-Profile: Isabelle Sermet-Gaudelus, Philippe Reix
Förderung
- This study was supported by the French patient organization "Vaincre La Mucoviscidose", which participated in providing data from the French Registry, in the i…
Zitieren
APA
Guyot, E., Deygas, F., Belhassen, M., Berard, M., Van Ganse, E., Sermet-Gaudelus, I., Tiaiba, S., Dubus, J. C., Durieu, I., & Reix, P. (2025). Newborn Screening for Cystic Fibrosis Is Associated With the Lowest Healthcare Costs: A 10‐Year Observational Follow‐Up Study in France. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71134
Vancouver
Guyot E, Deygas F, Belhassen M, Berard M, Van Ganse E, Sermet-Gaudelus I, et al. Newborn Screening for Cystic Fibrosis Is Associated With the Lowest Healthcare Costs: A 10‐Year Observational Follow‐Up Study in France. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71134
BibTeX
@article{Guyot2025,
author = {Guyot, Erika and Deygas, Floriane and Belhassen, Manon and Berard, Marjorie and Van Ganse, Eric and Sermet-Gaudelus, Isabelle and Tiaiba, Sabrine and Dubus, Jean-Christophe and Durieu, Isabelle and Reix, Philippe},
title = {Newborn Screening for Cystic Fibrosis Is Associated With the Lowest Healthcare Costs: A 10‐Year Observational Follow‐Up Study in France},
journal = {Pediatric Pulmonology},
year = {2025},
doi = {10.1002/ppul.71134}
}
EUVIMED